NCT06503263View on ClinicalTrials.gov

Zanubrutinib and Lenalidomide as Maintenance Therapy in DLBCL

PHASE2RecruitingINTERVENTIONAL
Enrollment

240

Participants

Timeline

Start Date

August 30, 2024

Primary Completion Date

July 30, 2030

Study Completion Date

December 30, 2030

Conditions
Diffuse Large B-cell Lymphoma
Interventions
DRUG

Zanubrutinib plus Lenalidomide as Maintenance Therapy

Patients were treated by Zanubrutinib(160mg po bid d1-28) plus Lenalidomide(25mg po qd d1-14) as maintenance therapy until 2 years post chemotherpay

Trial Locations (1)

100048

RECRUITING

Navy General Hospital, Beijing

All Listed Sponsors
lead

Navy General Hospital, Beijing

OTHER